Why the study?
Determining optimal perioperative antiplatelet management is a common and challenging clinical problem, particularly for patients with coronary stents receiving dual antiplatelet therapy.
How should patients receiving single or dual antiplatelet therapy be managed perioperatively for noncardiac and cardiac surgery?
How should patients receiving single or dual antiplatelet therapy be managed perioperatively for noncardiac and cardiac surgery?
This review provides a case-based, evidence-informed approach to the perioperative management of antiplatelet therapy in patients undergoing noncardiac and cardiac surgery.
Informs perioperative DAPT decisions in stented patients; leaves open optimal individualized strategies pending further trials.
Addressing the optimal management approach for patients who are receiving single or dual antiplatelet therapy is a common and sometimes challenging clinical problem, especially for patients with coronary stents who are receiving dual antiplatelet therapy with acetylsalicylic acid (ASA) combined with a P2Y12 inhibitor. Using a case-based format, we summarize the findings of recent clinical trials and key observational studies which help inform best practices for the perioperative antiplatelet management of noncardiac surgery and coronary artery bypass graft surgery. In this review, we explore the evidence to address 3 key questions: What is the minimum duration that a surgery should be delayed after coronary stent implantation? In patients who are receiving single antiplatelet therapy with ASA, how to manage patients who require noncardiac and cardiac surgery? In patients who are receiving dual antiplatelet therapy for a coronary stent, how to manage patients who require noncardiac and cardiac surgery?
No takes yet. Share an insight, caveat, or question.
Douketis et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: